Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.
about
Current Trends of Renal Impairment in Multiple MyelomaMultiple myeloma in the very elderly patient: challenges and solutionsRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsDefining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasiasInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationIncidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsAdvances in understanding prognosis in myeloma.Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Renal failure in multiple myeloma: incidence, correlations, and prognostic significance.The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.Bortezomib in patients with renal impairment.Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study.Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment.Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.Update on the optimal use of bortezomib in the treatment of multiple myelomaHypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel anti-myeloma therapies.A systems biology approach to invasive behavior: comparing cancer metastasis and suburban sprawl developmentThe impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myelomaNovel therapies in multiple myeloma for newly diagnosed nontransplant candidatesCase report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy.Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity scoreRedeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain productionRisk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma.Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based RegimensImpact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaThe safety of zoledronic acid.Immunodeficiency and immunotherapy in multiple myeloma.
P2860
Q26740444-97EB0B8B-8912-4D58-A53A-C36FD09F766AQ26752991-E194C34C-227F-476F-AE8C-FF1D23718110Q26851417-2E41A0AB-0633-4835-A1C6-661C8D4F37D9Q26861037-ACC3827F-A341-450A-9652-217CC8103079Q27002668-AA70198C-7107-4ABF-B811-7AB2915666A1Q27014143-594F72B3-6EF6-4857-8CBD-1B89EA2EBBDCQ28084683-532E4F34-79DB-4A9E-B81F-5F7F2A232282Q30244061-BE173EBF-9EC6-4962-A866-B674D5CF03C8Q30595175-69BF5AF9-D6C6-4961-AF9D-7143ACFED501Q33374368-415E16B0-75DC-4406-A5ED-2D3643F1833CQ33390284-C74EAFD5-242B-40D5-835A-FA2714D41F83Q33396250-D0F945C7-1758-4157-A87C-6737CF1B623DQ33397490-1D95139B-A9E0-46FD-B2D2-635B56CF46C5Q33398587-2111AF5F-85F1-4335-9552-A69648899C63Q33407105-40CF2DED-FFCD-4A95-B7BC-5CEDDE4E994BQ33409681-04AEB5BE-7DF9-430D-83CC-53B7A70C0951Q33411708-54DE5BF4-E85E-45DD-83C3-1493FC314B92Q33418712-434B38E8-33AC-44BA-A4B3-B74DEE1AD3DEQ33421008-82E176D9-A9A8-4440-ADE9-840796D970C1Q33426615-53604F34-5B89-440B-96BE-AE85D8D7AE5AQ33434435-390A1A25-DAAB-449B-82B7-73EB60797F9BQ33440007-8451F957-DFD3-4B44-B4FC-B8782C66C90EQ33443274-118B606B-C4BA-4349-8F08-5FFBE1D1BD54Q33533975-58F47CF7-8EA9-4372-A1BE-ECF287871D42Q33562719-E11C6109-D853-462B-9C2D-5E700A222573Q33639796-635B9A24-3770-4136-BBBA-DE6272C9C7B7Q33874209-6C0DBF4F-F260-4C94-821E-30E8FEB5CA30Q34448964-D0D8581F-AD1D-46EE-8A8F-64091ADD9989Q34798105-758A52F7-DD74-4546-87DB-C6A85E9B4460Q34900554-A9C9C534-482D-4A98-AF9A-AF64EB2A3D09Q35066433-F3564E6F-D45E-48F3-9456-85E25C4B1AF6Q35244883-221E6C72-DC2F-4B61-A3CC-48B3E29C3DAEQ35664302-6C52B0C7-FFC2-4223-88BC-E692E72DB186Q35664315-BD74D033-AD75-4820-9016-6B6C67682BE5Q36240971-9C31E55E-3075-493D-B016-9936814EAC1CQ36524353-01DED71E-661E-4C81-9330-F9AE1FC56BBDQ36735810-69E590FC-517C-4149-BC02-818179A81735Q36750472-8E15B421-4135-4972-9A6A-AE873FAC3BFEQ36811542-FD18A5A6-DB6D-45CF-AF55-CDB46159688BQ36904977-C3CEC44D-D80C-4175-8B74-356B821AC871
P2860
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Early mortality after diagnosi ...... Adult Leukaemia Working Party.
@en
Early mortality after diagnosi ...... Adult Leukaemia Working Party.
@nl
type
label
Early mortality after diagnosi ...... Adult Leukaemia Working Party.
@en
Early mortality after diagnosi ...... Adult Leukaemia Working Party.
@nl
prefLabel
Early mortality after diagnosi ...... Adult Leukaemia Working Party.
@en
Early mortality after diagnosi ...... Adult Leukaemia Working Party.
@nl
P2093
P356
P1476
Early mortality after diagnosi ...... Adult Leukaemia Working Party.
@en
P2093
Alastair Smith
Bradley M Augustson
Faith Davies
Gareth Morgan
Gulnaz Begum
J Anthony Child
Janet A Dunn
Judith Behrens
Mark T Drayson
Nicola J Barth
P304
P356
10.1200/JCO.2005.03.2086
P407
P577
2005-11-07T00:00:00Z